Current donor management practices target macrohaemodynamic parameters, but it is unclear if this leads to improvements in microvascular perfusion and tissue oxygenation; the latter may have more impact on organ status. In a recent preclinical study we determined that brain death impaired tissue perfusion and oxygen utilisation in swine while pharmacologic correction of these deficits improved organ function and reduced markers of tissue injury. As a first step in translating the preclinical findings, we conducted a prospective observational study to determine if there was an association between peripheral tissue oxygenation (measured by near-infrared spectroscopy) in deceased by neurological criteria human donors and the number of organs transplanted. In 60 donors, the mean time-weighted average of tissue oxygenation was 87.5% (standard deviation, SD, 5.2%) and the average number of organs transplanted was 3.5 (SD 2); there was a positive linear relationship between these two parameters. A 5% rise in tissue oxygenation was associated with an increase of 0.47 organs transplanted (95% confidence intervals 0.16 to 0.78) after adjusting for age (P=0.004). No such correlations were observed for the macrohaemodynamic or macro-oxygenation parameters (including arterial blood oxygenation). The results of this clinical trial are consistent with our preclinical work and support the postulate that targeting the microvasculature to improve tissue perfusion and tissue oxygen delivery in human donors has the potential to increase the quantity of organs suitable for transplant.
Transplantation is an accepted intervention to correct innate organ failure but is dependent upon organ availability. In April of 2018 there were over 115,000 Americans registered on the United Network for Organ Sharing (UNOS) waiting list while for all of 2017 just over 28,000 solid organ transplantations occurred. On average, 20 people die each day in the US before their transplant needs are met. This gross discrepancy is not new but has worsened in recent years as increases in the number of available organs have been significantly outpaced by the rise in transplant candidates 1 . Further exacerbating this situation is that the number of organs recovered per donor (ORPD) is far less than 100%. Out of the eight commonly transplanted organs (two kidneys, two lungs, heart, liver, pancreas, and intestine) the actual yield has remained stubbornly below 50% 2 . The national average is 3.4 ORPD with the rate as low as 2.8 in some areas of the country. Procurement rates are between 60% and 70% for kidneys and livers, but drop to 20% to 40% for heart and lungs. Optimising donor status is an obvious strategy to increase the number of transplantable organs but the actual means to accomplish this goal-correcting the physiological instability produced by brain death (BD)-remains unclear 3 . The period during and immediately following BD is characterised by physiological instability, the result first of intense sympathetic stimulation and significant release of catecholamines (the Cushing response; sympathetic storm) with transient vasoconstriction, hypertension, and tachycardia followed by the complete loss of sympathetic activity leading to hypotension and profound reduction in systemic vascular resistance 4 . Both conditions result in impaired organ blood flow and tissue ischaemia.
Once BD is confirmed, care of the patient switches from restorative to supportive as donation status is assessed. Current donor management strategies target macrohaemodynamic parameters to correct physiological instability with the goal of limiting systemic organ ischaemia and reperfusion injury (see Supplemental Methods, available on AIC website) 5 . The acidosis and systemic effects of BD can be controlled to some extent by altering ventilation rates and/or administration of vasoactive agents. However, such interventions have minimal ability to preserve end-organ blood flow and oxygen delivery. This is because local tissue blood flow, rather than arterial blood oxygen content, is the primary determinant of oxygen delivery. Thus, a focus on manipulating global parameters such as blood pressure, blood oxygen content, etc, may fail to impact microvascular blood flow, tissue perfusion, and oxygen delivery. Even with the appearance of normal vital signs after early goaldirected therapy, critically ill patients often remain in an occult hypoxic hypoperfused state that negatively impacts organ function and worsens outcome 6 . In this regard, useful actable clinical information on donor microparameters (viz. tissue oxygenation) could be readily obtained by the use of non-invasive, low-cost, and low-risk spectroscopic methods, notably near-infrared spectroscopy (NIRS).
The diagnostic potential of NIRS as a means to noninvasively monitor tissue oxygenation was first put forth by Franz Jobsis 7 , with subsequent development focusing on cerebral oximetry-there are now several commercial devices available for recording human brain tissue oxygen saturation (StO 2 ) 8 . Following on this neurologic focus has been the more recent development of NIRS peripheral oximetry systems as a means of tracking systemic tissue oxygenation and predicting changes in organ function 9 . As a result of previous studies demonstrating the clinical diagnostic potential of peripheral NIRS oximetry (i.e. improved StO 2 correlated with reduced morbidity and mortality) 10, 11 , we designed this study to evaluate the technology as a novel means to monitor consented donors after declaration of death by neurological criteria (DNC). We hypothesised that higher StO 2 values would be associated with an increased number of organs transplanted per donor. A secondary goal of this prospective observational study was to provide initial guidance on what the target StO 2 should be in this population to guide directed therapeutic interventions.
Methods

Study population
This investigation was a prospective blinded observational study conducted in Northeast Ohio. The target population was consented DNC organ donors ≥15 years of age and weighing ≥45 kg. Living donors and individuals declared deceased after circulatory determination of death were not studied. The study protocol was cleared by the Institutional Review Board of the Cleveland Clinic as non-living subjects research (Protocol # 13-020) and approved by the Medical Advisory Board and Board of Directors of the local organ procurement organisation, Lifebanc (Cleveland, OH, USA). Authorisation for research participation was obtained by either premorbid first person consent or from the donor's next of kin as a component of the organ donation consent process. This study used data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, wait-listed candidates, and transplant recipients in the US, submitted by the members of the OPTN. The Health Resources and Services Administration (HRSA), US Department of Health and Human Services, provides oversight to the activities of the OPTN contractor.
Study protocol
Research personnel were contacted about eligible subjects by the Lifebanc donor management team with the goal of starting StO 2 monitoring as soon as possible after initiation of standard donor management (see Supplement). A NIRS probe was placed on the thenar eminence and connected to an InSpectra Tissue Spectrometer (Hutchinson Technology Inc; Hutchinson, MN, USA). The StO 2 values were continuously recorded by the monitoring device until organ recovery. The device's output screen was made opaque to ensure that the StO 2 measure was not used to influence donor management. The care team was alerted by the device to any loss of signal and the members had been instructed on how to re-secure the probe in case of accidental displacement.
Data collection and analysis
Sample size projections were calculated from published reports on 1) DNC donors with a mean (standard deviation, SD) number of transplantable organs of 3.01 (SD 1.78) 12 and 2) StO 2 monitoring in critical care settings that estimated the SD to be between 7% and 14% (on the StO 2 scale of 0-100%) 13 . Using these parameters, a sample size projection of 58 donors was based on having a 90% power to detect a clinically meaningful treatment effect (defined as a 10% difference in StO 2 to yield at least one more transplantable organ). Our a priori estimation assumed SDs of 8% for StO 2 13 and two for the number of procured organs 12 . We thus aimed to enrol 60 subjects.
Information on donor demographics, physiological status, and interventions conducted during the management phase were collected from the medical record and are presented as number (percentage), mean (SD) or median (interquartile range, IQR). Multivariable linear regression analysis was used to test the primary hypothesis. We used time-weighted average (TWA) of StO 2 for this analysis as the summary measure of the whole donor management phase. Potential confounders (Table S1 ) were included in the final model.
As a sensitivity analysis, we assessed StO 2 in the context of predicted number of transplantable organs to account for pre-existing conditions (e.g. kidney disease) that reduced the potential number of available solid organs down from eight (heart, two lungs, two kidneys, liver, pancreas and intestine). Further sensitivity analyses were conducted on the association between TWA of StO 2 and the number of organs transplanted or recovered, the number not recovered, and the difference between transplanted and expected (based on the OPTN-SRTR [Scientific Registry of Transplant Recipients] Organ Yield Calculator) 14 . The significance criterion (0.0125) was adjusted for multiple comparisons (Bonferroni correction). Secondary analyses were conducted to evaluate the associations between TWA of StO 2 and macrohaemodynamic measurements. Bonferroni correction was again employed to adjust for multiple comparisons.
SAS software (Version 9.3, SAS Institute; Cary, NC, USA) was used for all outcome analyses while PASS software (Version 11, NCSS, LLC; Kaysville, UT, USA) was used for the sample size estimation. Additional details on the data analysis are provided in the Supplement.
Results
We enrolled 60 consecutive donors between April 2013 and March 2014. Demographic information for the subjects is provided in Table 1 , with additional donor characteristics available in Table S1 of the Supplement. The median interval time between declaration of brain death and start of StO 2 monitoring was 6.6 hours (IQR 4.8-8.6, range 0-37) reflecting the time required to notify the research staff and to transport the monitoring equipment to the specific hospital. The median time to initiate donor management after consent was 1.7 hours (IQR 0.4-3.1, range 0-23). The median duration of StO 2 monitoring was 26.1 hours (IQR 16.34-34.9, range 3.6-60) out of 36.9 hours (IQR 28.7-46.3, range 10.8-66.6) of donor management. All subjects were successfully taken to the operating room for recovery of organs at the end of the donor management phase. Initial and final laboratory and macrohaemodynamic data, as well as therapeutic interventions, are listed in Tables S2 and S3 of the Supplement.
The observed average TWA of StO 2 during the donor management period was 87.5% (SD 5.2%) and the average number of organs transplanted per donor was 3.5 (SD 2.0). Normal (healthy) human StO 2 measure for the InSpectra device is reported to be 81% (SD 9%) 15 . The unadjusted association between these two variables is displayed in Figure 1 ; higher TWA of StO 2 was associated with more organs transplanted per donor (P=0.004), after adjusting for age (the only covariate that was retained). The estimated multivariable slope coefficient was 0.47 (95% confidence intervals, CI, 0.16 to 0.78), i.e. an expected increase of 0.47 organs transplanted for a 5% increase in tissue oxygenation. The sensitivity analyses yielded supporting results (Table 2 ) with higher TWA of StO 2 associated with trends towards higher number of organs transplanted or recovered (P=0.09), numbers of organs expected to be transplanted (P=0.25), and difference between transplanted and expected numbers of organs (P=0.16). Importantly, there was no significant association between StO 2 and pulse oximetry (SpO 2 ) (measure recorded hourly from a pulse oximeter; Figure  2A ) and no correlation between SpO 2 and the number of organs transplanted ( Figure 2B ; P=0.74). Similarly there were no significant associations between StO 2 and the recorded macrohaemodynamic parameters (including arterial oxygen saturation [SaO 2 ] measures quantified using a blood gas co-oximeter; Supplement Table S4 ). The reasons for discarding organs for transplantation are listed in Table S5 of the Supplement. We had no control over the organs following surgical procurement, which prevented us from assessing StO 2 and post-graft function.
We also attempted to identify the StO 2 value(s) important for increasing organ yield- Figure 3 is a boxplot of the difference between the expected and actual number of organs transplanted across the TWA StO 2 ranges. Our analyses suggest that a TWA of >85% may increase the difference between expected and actual number of organs transplanted while a TWA of StO 2 of <80% or an StO 2 nadir of <75% may portend a reduction in this number. A breakdown of specific organs transplanted per each range of TWA of StO 2 is provided in Table 3 . 
Discussion
In this first study to monitor tissue oxygenation in DNC donors, we found that peripheral StO 2 is associated with the number of organs transplanted per donor. This suggests that donor management strategies targeted at achieving increases in StO 2 may lead to increases in organs transplanted per donor.
Donor management in the Western world is initiated after the declaration of BD and the gift of donation has been made. After death, supportive care is currently aimed at negating the adverse systemic effects of the brain herniation process by manipulating mechanical ventilation, and administration of fluids, blood products and/or vasoactive agents. Additional benefit in this regard may be obtained from hormonal replacement therapies that can aid in the conversion from anaerobic to aerobic cellular metabolism. However, such manipulations are currently titrated using macrohaemodynamic parameters, which may not be ideal. In addition, the degree of physiological monitoring is not standardised for this patient population-for example few donors can be expected to have invasive haemodynamic monitoring such as a Swan-Ganz catheter in place premortem because such monitoring has no impact on intensive care unit (ICU) survival 16 . Despite good adherence to a standard donor maintenance protocol in the present study we observed poor correlations between StO 2 and the typically monitored macroparameters including blood oxygen saturation (both SpO 2 and SaO 2 ). We believe that tissue perfusion monitoring is a potential target for donor management in order to increase organ transplant rates.
The tissue oxygenation measure calculated by the NIRS device (StO 2 ) is analogous to a mixed venous measurement reflecting haemoglobin (Hb) oxygenation in the capillaries, venules, and arterioles of the region of interest. This is in contrast to the SpO 2 measure calculated by the pulse oximeter, which requires a detectable pulse and is derived from Hb in the arteries-StO 2 is a microparameter while SpO 2 (like the SaO 2 measure obtained from a blood gas machine) is a macroparameter, i.e. tissue versus arterial oxygen content. In critically ill patients, persistence of low StO 2 levels despite adequate resuscitation has been associated with increased risk of multi-organ dysfunction, morbidity, and death 17 . We have previously observed this disconnect between arterial blood oxygen content and StO 2 in diverse patient populations, including children undergoing cardiopulmonary bypass 18 . A similar microvascular effect appears to be occurring in our donor cohort where lower StO 2 levels were recorded even in the presence of high SpO 2 and SaO 2 values, and it was tissue not arterial oxygenation that was prognostic for the number of viable organs recovered for transplantation.
The disconnect between measures of tissue and arterial oxygenation reflect the fact that tissue blood flow and not blood oxygen content is the primary determinant of oxygen delivery and thus tissue oxygenation 19 . As first described by Guyton 20 , blood flow is regulated substantially by hypoxic vasodilation, a physiological process that couples metabolic demand (oxygen requirement) to local tissue perfusion 21 . Red blood cells (RBC) are the main mediator of this response as they act as conduits of nitric oxide (NO) bioactivity. NO is carried by Hb in the form of an S-nitrosothiol (SNO), i.e. S-nitrosohaemoglobin (SNO-Hb). The transition from high to low oxygen tension in the arterial periphery subserves the release from RBC not only of oxygen but also of this SNObased vasodilatory activity. This finely tuned system with its complex interactions between oxygen, NO, and Hb
22
, allows for second-by-second changes in microcirculatory flow. In this milieu Hb is not just an oxygen carrier, it is an oxygen sensor and a hypoxia-responsive transducer of NO signals 23 .
Vasodilation by SNO-Hb (i.e. release of NO bioactivity) is linked to Hb desaturation and thus provides a regulated mechanism for matching blood flow and oxygen delivery with local metabolic demand 19 . The increased number of transplantable organs from subjects who maintained higher levels of StO 2 (e.g. >85% as recorded by the InSpectra device) supports including this measurement as a new target for donor management strategies. Following declaration of death, supportive care aims to maintain organ perfusion. However, despite good adherence to a standard donor maintenance protocol we observed poor correlations between StO 2 and the typical macrohaemodynamic parameters-a perhaps not surprising result since the current protocols do not specifically target NO bioactivity and RBC physiology. Nonetheless, the relationship between SNO-Hb and tissue oxygenation provides for a potential druggable target, one that would reduce the need for high oxygen and aggressive ventilatory strategies that harm the lungs and could reduce the use of pressors that can induce adrenergic tachyphylaxis in the heart. Indeed, several clinical 24, 25 and preclinical trials 26, 27 have demonstrated the therapeutic benefits of renitrosylation, which acts to restore or enhance RBC-derived NO bioactivity. Of specific relevance to the current findings, we recently demonstrated in a clinical trial that pharmacological elevation of SNO-Hb increased StO 2 in healthy subjects under hypoxia (FiO 2 =0.12) 28 . And in a large animal preclinical model of donor support, increasing SNO-Hb after BD improved tissue blood flow and oxygenation, reduced markers of immune activation and cellular injury, and preserved organ function 29 .
The significance of our findings is limited somewhat by the observational nature of the study although it is strengthened by focusing on a single organ procurement organisation as all subjects received the same level of care during the pre-procurement phase. Certainly a prospective comparative effectiveness trial that explicitly determines if improving StO 2 increases organ yield is warranted. In the current setting the clinical care team was kept unaware of the StO 2 measures. A consequence of this is that the clock on the InSpectra NIRS machine was not synchronised with the electronic medical record. By extension we are not able to link specific manipulations with increases or decreases in tissue oxygenation. Another concern is with the tissue oxygenation measure itself. We found higher StO 2 levels were beneficial but we are not in a position to identify a target value or a value below which active intervention is required. Furthermore, there is discordance between NIRS devices as to the actual StO 2 measure with wide variances reported to the extent that inter-system comparisons are not possible at this time [30] [31] [32] . Nonetheless, by using a single NIRS device we found that higher time-weighted StO 2 measures are associated with increased number of organs transplanted per donor. We suggest that StO 2 monitoring may aid in overall donor management and that administration of agents that target the microvasculature to improve tissue perfusion could increase the number of transplantable organs.
